Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Emory University TAP Pharmaceutical Products Inc. |
---|---|
Information provided by: | Emory University |
ClinicalTrials.gov Identifier: | NCT00239551 |
The purpose of this study is to measure the prostaglandin levels in patients with stress ulcer and the effect of Prevacid on prostaglandin levels in patients with stress ulcer.
Condition | Intervention | Phase |
---|---|---|
Stomach Ulcer |
Drug: Prevacid |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer |
Estimated Enrollment: | 30 |
Study Start Date: | October 2005 |
The prostaglandin system plays an important role in the gastric mucosa to strengthen its resistance against injury. Critically ill patients are at greatest risk of developing stress-related gastric mucosal lesions. Although the levels of prostaglandins in gastric mucosa in patients with stressed animal has been studied, prostaglandin levels in the gastric mucosa in patients with stress ulcer have not been studied and the effect of Prevacid on prostaglandin levels in gastric mucosa from patients with stress ulcer is unknown.
We hypothesize that prostaglandin levels are low in the gastric mucosa in patients with stress ulcer, and Prevacid is an effective agents in increasing prostaglandin levels in the gastric mucosa in stress stress ulcer.
Comparison(s): The prostaglandin levels in patients who treated with Prevacid for stress ulcer, compared to the prostaglandin levels in patients who treated with H2 blocker for stress ulcer.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Qiang Cai, MD, PhD | 404-778-4857 | qcai@emory.edu |
United States, Georgia | |
Emory University School of Medicine | Recruiting |
Atlanta, Georgia, United States, 30322 | |
Contact: Qiang Cai, MD, PhD 404-778-4857 qcai@emory.edu | |
Principal Investigator: Qiang Cai, MD, PhD | |
Sub-Investigator: Vincent W Yang, MD, PhD |
Principal Investigator: | Qiang Cai, MD, PhD | Emory University |
Study Director: | Vincent W Yang, MD, PhD | Emory University |
Study ID Numbers: | 623-2005 |
Study First Received: | October 13, 2005 |
Last Updated: | September 11, 2006 |
ClinicalTrials.gov Identifier: | NCT00239551 |
Health Authority: | United States: Institutional Review Board |
gastric stress ulcer Prevacid Prostaglandin |
Stomach Ulcer Stomach Diseases Digestive System Diseases Gastrointestinal Diseases |
Ulcer Stress Lansoprazole Peptic Ulcer |
Anti-Infective Agents Pathologic Processes Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Anti-Ulcer Agents Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |